Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2011
    Regulated GDNF Gene Therapy: a Novel Regulatory System Based on Protein Degradation

    Objective/Rationale:
    Gene therapy may offer effective treatments to patients. Delivering genes to cells in the body has the potential of letting the patient’s cells treat themselves. In the case of...

  • MJFF Research Grant, 2011
    Global Estimates for the Role of LRRK2 Variation in Parkinson's Disease Susceptibility

    Promising Outcomes of Original Grant:
    Our original goal was to resolve the role of known LRRK2 coding variants in susceptibility to Parkinson’s disease. Our studies have nominated risk factors for...

  • Coordination of Clinical and Biological Collections for the, 2011
    Coordination of Clinical and Biological Collections for the LRRK2 Cohort Consortium

    Objective/Rationale: 
    MJFF is funding multiple international LRRK2 cohorts to gain insight into the relationship of this genetic mutation to Parkinson’s disease. Using standardized methods...

  • Therapeutics Development Initiative, 2011
    Pharmacological Testing of Nurr1 Agonists in Pre-clinical Models of Parkinson's Disease

    Objective/Rationale: 
    Sanofi-aventis has identified Nurr1 receptor agonists whose in vitro pharmacological activity, together with literature data, indicate that Nurr1 agonists could provide a novel...

  • MJFF Research Grant, 2011
    Drug Rescue of PINK1 Kinase Activity - A New Therapeutic Modality For Treating PD

    Objective/Rationale: 
    Many genetic disorders are caused by the loss of a functional protein which protects cells from disease. These disorders are difficult to treat with drugs because most drugs block...

  • Target Validation, 2011
    Gene delivery of miRNAs to reduce alpha synuclein: a new therapy for PD

    Objective/Rationale: 
    Alpha synuclein is a protein that in excessive amounts is implicated in Parkinson’s disease (PD). Alpha synuclein is also known to be the major constituent of a signature...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.